CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
DNL201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03710707
NCT03710707Phase 1Completed
CompareCT.gov

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease

Denali Therapeutics Inc.·interventional·Posted Oct 18, 2018·Updated Jan 13, 2020

In Brief

A Phase 1 clinical trial evaluating DNL201 and Placebo for Parkinson Disease. Completed, enrolled 29 participants across 7 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 18, 2018
Enrollment StartDec 4, 2018
Primary CompletionDec 6, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.7 years ago

Interventions

DNL201drug

Oral repeating dose

Placebodrug

Oral repeating dose